{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:27:04Z","timestamp":1774452424164,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["#5T32HL007028-44"],"award-info":[{"award-number":["#5T32HL007028-44"]}]},{"name":"NIH","award":["#R21AR075134"],"award-info":[{"award-number":["#R21AR075134"]}]},{"name":"NIH","award":["#1R21EY029391"],"award-info":[{"award-number":["#1R21EY029391"]}]},{"name":"Pfizer US Pharmaceuticals Group grant","award":["53857367"],"award-info":[{"award-number":["53857367"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["#U54 AR057319"],"award-info":[{"award-number":["#U54 AR057319"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["#U54 RR019497"],"award-info":[{"award-number":["#U54 RR019497"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess markers of neutrophil activation such as calprotectin and N-formyl methionine (fMET) in anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) and large-vessel vasculitis (LVV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Levels of fMET, and calprotectin, were measured in the plasma of healthy controls (<jats:italic>n<\/jats:italic>=30) and patients with AAV (granulomatosis with polyangiitis (GPA,<jats:italic>n<\/jats:italic>=123), microscopic polyangiitis (MPA,<jats:italic>n<\/jats:italic>=61)), and LVV (Takayasu\u2019s arteritis (TAK,<jats:italic>n<\/jats:italic>=58), giant cell arteritis (GCA,<jats:italic>n<\/jats:italic>=68)), at times of remission or flare. Disease activity was assessed by physician global assessment. In vitro neutrophil activation assays were performed in the presence or absence of formyl peptide receptor 1 (FPR1) inhibitor cyclosporine H.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Levels of calprotectin, and fMET were elevated in patients with vasculitis as compared to healthy individuals. Levels of fMET correlated with markers of systemic inflammation: C-reactive protein (<jats:italic>r<\/jats:italic>=0.82,<jats:italic>p<\/jats:italic>&lt;0.0001), and erythrocyte sedimentation rate (<jats:italic>r<\/jats:italic>=0.235,<jats:italic>p<\/jats:italic>&lt;0.0001). The neutrophil activation marker, calprotectin was not associated with disease activity. Circulating levels of fMET were associated with neutrophil activation (<jats:italic>p<\/jats:italic>&lt;0.01) and were able to induce de novo neutrophil activation via FPR1-mediated signaling.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Circulating fMET appears to propagate neutrophil activation in AAV and LVV. Inhibition of fMET-mediated FPR1 signaling could be a novel therapeutic intervention for systemic vasculitides.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13075-022-02849-z","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T08:03:13Z","timestamp":1656489793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis"],"prefix":"10.1186","volume":"24","author":[{"given":"Despina","family":"Michailidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhargavi","family":"Duvvuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runa","family":"Kuley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cuthbertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader A.","family":"Khalidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curry L.","family":"Koening","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"Langford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A.","family":"McAlear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry W.","family":"Moreland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Pagnoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine G.","family":"Sreih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Warrington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Mustelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Monach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"7","key":"2849_CR1","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ni.2921","volume":"15","author":"WM Nauseef","year":"2014","unstructured":"Nauseef WM, Borregaard N. Neutrophils at work. Nat Immunol. 2014;15(7):602\u201311.","journal-title":"Nat Immunol"},{"key":"2849_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-020712-164023","volume":"9","author":"TN Mayadas","year":"2014","unstructured":"Mayadas TN, Cullere X, Lowell CA. The multifaceted functions of neutrophils. Annu Rev Pathol. 2014;9:181\u2013218.","journal-title":"Annu Rev Pathol"},{"issue":"5","key":"2849_CR3","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1172\/JCI84538","volume":"126","author":"OE Sorensen","year":"2016","unstructured":"Sorensen OE, Borregaard N. Neutrophil extracellular traps - the dark side of neutrophils. J Clin Invest. 2016;126(5):1612\u201320.","journal-title":"J Clin Invest"},{"issue":"1","key":"2849_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.13392","volume":"199","author":"CM de Bont","year":"2020","unstructured":"de Bont CM, Eerden N, Boelens WC, et al. Neutrophil proteases degrade autoepitopes of NET-associated proteins. Clin Exp Immunol. 2020;199(1):1\u20138.","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2849_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/art.41062","volume":"72","author":"M Bach","year":"2020","unstructured":"Bach M, Moon J, Moore R, et al. A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2020;72(1):47\u201356.","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"2849_CR6","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3899\/jrheum.190875","volume":"47","author":"S Moore","year":"2020","unstructured":"Moore S, Juo HH, Nielsen CT, et al. Role of Neutrophil Extracellular Traps Regarding Patients at Risk of Increased Disease Activity and Cardiovascular Comorbidity in Systemic Lupus Erythematosus. J Rheumatol. 2020;47(11):1652\u201360.","journal-title":"J Rheumatol"},{"issue":"2","key":"2849_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/art.41078","volume":"72","author":"B Duvvuri","year":"2020","unstructured":"Duvvuri B, Pachman LM, Morgan G, et al. Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis. Arthritis Rheumatol. 2020;72(2):348\u201358.","journal-title":"Arthritis Rheumatol."},{"key":"2849_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fimmu.2016.00256","volume":"7","author":"D Soderberg","year":"2016","unstructured":"Soderberg D, Segelmark M. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis. Front Immunol. 2016;7:256.","journal-title":"Front Immunol"},{"issue":"1","key":"2849_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6(1):71.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"2849_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","volume":"10","author":"JC Jennette","year":"2014","unstructured":"Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol. 2014;10(8):463\u201373.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"2849_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2249.1990.tb03336.x","volume":"81","author":"Y Deguchi","year":"1990","unstructured":"Deguchi Y, Shibata N, Kishimoto S. Enhanced expression of the tumour necrosis factor\/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis. Clin Exp Immunol. 1990;81(2):311\u20134.","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2849_CR12","doi-asserted-by":"publisher","first-page":"R140","DOI":"10.1186\/ar3873","volume":"14","author":"J Yuan","year":"2012","unstructured":"Yuan J, Gou SJ, Huang J, et al. C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther. 2012;14(3):R140.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2849_CR13","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4049\/jimmunol.153.3.1271","volume":"153","author":"AJ Porges","year":"1994","unstructured":"Porges AJ, Redecha PB, Kimberly WT, et al. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol. 1994;153(3):1271\u201380.","journal-title":"J Immunol"},{"issue":"2","key":"2849_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3899\/jrheum.110652","volume":"39","author":"PC Grayson","year":"2012","unstructured":"Grayson PC, Tomasson G, Cuthbertson D, et al. Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol. 2012;39(2):303\u20139.","journal-title":"J Rheumatol"},{"issue":"4","key":"2849_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/MD.0b013e3181af70c1","volume":"88","author":"K Maksimowicz-McKinnon","year":"2009","unstructured":"Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore). 2009;88(4):221\u20136.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"2849_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/nm.4027","volume":"22","author":"C Lood","year":"2016","unstructured":"Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22(2):146\u201353.","journal-title":"Nat Med"},{"issue":"7285","key":"2849_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature08780","volume":"464","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104\u20137.","journal-title":"Nature."},{"key":"2849_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.trsl.2018.07.014","volume":"202","author":"B Banoth","year":"2018","unstructured":"Banoth B, Cassel SL. Mitochondria in innate immune signaling. Transl Res. 2018;202:52\u201368.","journal-title":"Transl Res"},{"issue":"1","key":"2849_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1084\/jem.155.1.264","volume":"155","author":"H Carp","year":"1982","unstructured":"Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med. 1982;155(1):264\u201375.","journal-title":"J Exp Med"},{"issue":"5","key":"2849_CR20","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ajpath.2015.01.020","volume":"185","author":"DA Dorward","year":"2015","unstructured":"Dorward DA, Lucas CD, Chapman GB, et al. The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation. Am J Pathol. 2015;185(5):1172\u201384.","journal-title":"Am J Pathol"},{"issue":"11","key":"2849_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1471-4906(02)02316-5","volume":"23","author":"Y Le","year":"2002","unstructured":"Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol. 2002;23(11):541\u20138.","journal-title":"Trends Immunol"},{"issue":"2","key":"2849_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.smim.2016.03.004","volume":"28","author":"N Thieblemont","year":"2016","unstructured":"Thieblemont N, Wright HL, Edwards SW, et al. Human neutrophils in auto-immunity. Semin Immunol. 2016;28(2):159\u201373.","journal-title":"Semin Immunol"},{"issue":"6002","key":"2849_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1126\/science.1195491","volume":"330","author":"B McDonald","year":"2010","unstructured":"McDonald B, Pittman K, Menezes GB, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science. 2010;330(6002):362\u20136.","journal-title":"Science."},{"issue":"3 Suppl","key":"2849_CR24","doi-asserted-by":"publisher","first-page":"50S","DOI":"10.1007\/BF01538131","volume":"33","author":"CC Nast","year":"1988","unstructured":"Nast CC, LeDuc LE. Chemotactic peptides. Mechanisms, functions, and possible role in inflammatory bowel disease. Dig Dis Sci. 1988;33(3 Suppl):50S\u20137S.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"2849_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0016-5085(89)91410-8","volume":"97","author":"PA Anton","year":"1989","unstructured":"Anton PA, Targan SR, Shanahan F. Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's disease. Gastroenterology. 1989;97(1):20\u20138.","journal-title":"Gastroenterology."},{"key":"2849_CR26","doi-asserted-by":"publisher","first-page":"102630","DOI":"10.1016\/j.jaut.2021.102630","volume":"119","author":"B Duvvuri","year":"2021","unstructured":"Duvvuri B, Baddour AA, Deane KD, et al. Mitochondrial N-formyl methionine peptides associate with disease activity as well as contribute to neutrophil activation in patients with rheumatoid arthritis. J Autoimmun. 2021;119:102630.","journal-title":"J Autoimmun"},{"issue":"6","key":"2849_CR27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/art.23707","volume":"59","author":"AD Mahr","year":"2008","unstructured":"Mahr AD, Neogi T, Lavalley MP, Davis JC, et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener\u2019s granulomatosis. Arthritis Rheum. 2008;59(6):884\u201391.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2849_CR28","first-page":"178","volume":"27","author":"R Khandpur","year":"2013","unstructured":"Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;27(5):178.","journal-title":"Sci Transl Med"},{"issue":"6","key":"2849_CR29","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.4049\/jimmunol.0902199","volume":"184","author":"MF Denny","year":"2010","unstructured":"Denny MF, Yalavarthi S, Zhao W, et al. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol. 2010;184(6):3284\u201397.","journal-title":"J Immunol"},{"issue":"6","key":"2849_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.15698\/cst2019.06.190","volume":"3","author":"A Rodriguez-Nuevo","year":"2019","unstructured":"Rodriguez-Nuevo A, Zorzano A. The sensing of mitochondrial DAMPs by non-immune cells. Cell Stress. 2019;3(6):195\u2013207.","journal-title":"Cell Stress"},{"issue":"3","key":"2849_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF01409982","volume":"16","author":"JA Savige","year":"1996","unstructured":"Savige JA, Chang L, Wilson D, et al. Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Rheumatol Int. 1996;16(3):109\u201314.","journal-title":"Rheumatol Int"},{"issue":"2","key":"2849_CR32","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/rheumatology\/37.2.208","volume":"37","author":"R Manna","year":"1998","unstructured":"Manna R, Latteri M, Cristiano G, et al. Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases. Br J Rheumatol. 1998;37(2):208\u201310.","journal-title":"Br J Rheumatol"},{"issue":"12","key":"2849_CR33","first-page":"2446","volume":"34","author":"JK Sebastian","year":"2007","unstructured":"Sebastian JK, Voetsch B, Stone JH, et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol. 2007;34(12):2446\u201350.","journal-title":"J Rheumatol"},{"issue":"9","key":"2849_CR34","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.4049\/jimmunol.1701719","volume":"200","author":"M Gabl","year":"2018","unstructured":"Gabl M, Sundqvist M, Holdfeldt A, et al. Mitocryptides from human mitochondrial DNA-encoded proteins activate neutrophil formyl peptide receptors: receptor preference and signaling properties. J Immunol. 2018;200(9):3269\u201382.","journal-title":"J Immunol"},{"issue":"3","key":"2849_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/mp.51.3.143","volume":"51","author":"G Hetland","year":"1998","unstructured":"Hetland G, Talgo GJ, Fagerhol MK. Chemotaxins C5a and fMLP induce release of calprotectin (leucocyte L1 protein) from polymorphonuclear cells in vitro. Mol Pathol. 1998;51(3):143\u20138.","journal-title":"Mol Pathol"},{"issue":"6","key":"2849_CR36","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/ki.2013.2","volume":"83","author":"RJ Pepper","year":"2013","unstructured":"Pepper RJ, Hamour S, Chavele KM, et al. Leukocyte and serum S100A8\/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int. 2013;83(6):1150\u20138.","journal-title":"Kidney Int"},{"issue":"4","key":"2849_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00296-017-3881-4","volume":"38","author":"R Goel","year":"2018","unstructured":"Goel R, Nair A, Kabeerdoss J, et al. Study of serial serum myeloid-related protein 8\/14 as a sensitive biomarker in Takayasu arteritis: a single centre study. Rheumatol Int. 2018;38(4):623\u201330.","journal-title":"Rheumatol Int"},{"issue":"3","key":"2849_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11926-021-00980-5","volume":"23","author":"E Tombetti","year":"2021","unstructured":"Tombetti E, Hysa E, Mason JC, et al. Blood biomarkers for monitoring and prognosis of large vessel vasculitides. Curr Rheumatol Rep. 2021;23(3):17.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"2849_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/art.39814","volume":"69","author":"RJ Pepper","year":"2017","unstructured":"Pepper RJ, Draibe JB, Caplin B, et al. Association of serum calprotectin (S100A8\/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69(1):185\u201393.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2849_CR40","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1002\/art.39656","volume":"68","author":"C Lood","year":"2016","unstructured":"Lood C, Tyden H, Gullstrand B, et al. Platelet-Derived S100A8\/A9 and Cardiovascular Disease in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2016;68(8):1970\u201380.","journal-title":"Arthritis Rheumatol."},{"issue":"19","key":"2849_CR41","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1161\/CIRCULATIONAHA.105.607333","volume":"113","author":"AM Healy","year":"2006","unstructured":"Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113(19):2278\u201384.","journal-title":"Circulation."},{"issue":"8","key":"2849_CR42","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/rheumatology\/kez034","volume":"58","author":"Y van Sleen","year":"2019","unstructured":"van Sleen Y, Sandovici M, Abdulahad WH, et al. Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis. Rheumatology (Oxford). 2019;58(8):1383\u201392.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2849_CR43","doi-asserted-by":"publisher","first-page":"e0205982","DOI":"10.1371\/journal.pone.0205982","volume":"13","author":"L Martinez Valenzuela","year":"2018","unstructured":"Martinez Valenzuela L, Draibe J, Quero Ramos M, et al. Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis. PLoS One. 2018;13(10):e0205982.","journal-title":"PLoS One"},{"issue":"11","key":"2849_CR44","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1093\/rheumatology\/ket263","volume":"52","author":"H Tyden","year":"2013","unstructured":"Tyden H, Lood C, Gullstrand B, et al. Increased serum levels of S100A8\/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford). 2013;52(11):2048\u201355.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2849_CR45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.kint.2019.02.017","volume":"96","author":"J Everts-Graber","year":"2019","unstructured":"Everts-Graber J, Martin KR, Thieblemont N, et al. Proteomic analysis of neutrophils in ANCA-associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1 involved in apoptotic cell clearance. Kidney Int. 2019;96(2):397\u2013408.","journal-title":"Kidney Int"},{"issue":"9","key":"2849_CR46","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/art.41723","volume":"73","author":"RL Rhee","year":"2021","unstructured":"Rhee RL, Lu J, Bittinger K, et al. Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis With Polyangiitis. Arthritis Rheumatol. 2021;73(9):1703\u201312.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"2849_CR47","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.4049\/jimmunol.181.2.1429","volume":"181","author":"EL Southgate","year":"2008","unstructured":"Southgate EL, He RL, Gao JL, et al. Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils. J Immunol. 2008;181(2):1429\u201337.","journal-title":"J Immunol"},{"issue":"2","key":"2849_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/infdis\/jir713","volume":"205","author":"I Gjertsson","year":"2012","unstructured":"Gjertsson I, Jonsson IM, Peschel A, et al. Formylated peptides are important virulence factors in Staphylococcus aureus arthritis in mice. J Infect Dis. 2012;205(2):305\u201311.","journal-title":"J Infect Dis"},{"issue":"1","key":"2849_CR49","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1038\/s41467-019-11255-0","volume":"10","author":"JDJJ Ooi","year":"2019","unstructured":"Ooi JDJJ, Eggenhuizen PJ, Chua LL, et al. A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic auto-immunity. Nat Commun. 2019;10(1):3392.","journal-title":"Nat Commun"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02849-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02849-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02849-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T23:51:43Z","timestamp":1675986703000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02849-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2849"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02849-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"26 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the regional ethics board at the University of Washington, Seattle, WA, (#3100).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed written consent was obtained from all participants in accordance with the Helsinki Declaration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Michailidou received Advisory Board fees from ChemoCentryx. Dr. Khalidi received clinical trial support from BMS, Sanofi, and Abbvie; travel support from Astra Zeneca; and an Advisory Board fee from Roche. Dr. Koening served on the advisory board for Chemocentryx and Genentech. Dr. Specks reports receiving funds for the following activities: Consulting: AstraZeneca, ChemoCentryx. Research Support: AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Genentech\/Roche, InflaRx. Dr. Sreih works at Bristol-Myers Squibb and owns Astra Zeneca and Alexion Stocks. Dr. Warrington received clinical trial support from Eli Lilly and Kiniksa. Dr. Monach received consulting fees from Kiniksa, Celgene\/BMC, and ChemoCentryx. Dr. Merkel reports receiving funds for the following activities: Consulting and Research Support: AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech\/Roche, Genzyme\/Sanofi, GlaxoSmithKline, InflaRx, Takeda. Consulting only: CSL Behring, Dynacure, EMDSerono, Janssen, Kiniksa, Kyverna, Magenta, MiroBio, Neutrolis, Novartis, Pfizer, Sparrow, Talaris. Royalties: UpToDate. Dr. Mustelin received consulting fees from Cugene, Kiniksa, Miro Bio, and QiLu Pharmaceuticals; has an ownership share in Amdax; and has received research funding from Gilead Sciences. Dr. Lood received research funding from Exagen Inc, Pfizer, Gilead Sciences, and Eli Lilly.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}